Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 408

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 408
---
 |     |       $— |    |     |      $— |          |     |       $— |    |     | $—             |    |     | $—           |          |     |       $— |
|                                                                                            | 2023 |     |      | $11,280(3) |     |          | $— |     |         | $149,633 |     |          | $— |     |                | $— |     |              | $160,913 |     |          |

| (1) | Represents the portion of Dr. Lang’s salary attributable to his services to Channel during the year ended December 31, 2023. Dr. Lang was appointed Chief Medical Officer of Channel, effective May 15, 2023. |

| (2) | Mr. Kopfli stepped down as Chief Financial Officer with the hiring of Mr. Knuettel, effective June 10, 2022. In addition, in July 2023, Mr. Knuettel assumed the role of Interim Chief Executive Officer and stepped down as Chief Strategy Officer, and Mr. Kopfli was appointed Vice Chairman and Chief Strategy Officer. On December 1, 2023, Channel terminated Mr. Kopfli as Vice Chairman and Chief Strategy Officer. |

| (3) | Represents the portion of Mr. Kopfli’s salary attributable to his services to Channel during the years ended December 31, 2023. |

Employment Agreements and Arrangements Christian Kopfli Channel was a party to an amended and restated employment agreement with Christian Kopfli, dated July 28, 2023. Pursuant to such agreement, Mr. Kopfli agreed to serve as Channel’s Vice Chairman and Chief Strategy Officer, in consideration for an annualized salary of $275,000, payable in cash at the rate of $5,000 per month (a minimum of $1,125 per week), with the remainder accrued and paid as of the earliest of a sale or liquidation of Channel, Channel’s bankruptcy or three days after the approval by the Channel board of directors of a funded budget with appropriately established milestones subsequent to the effective date of a Form S-1 registration statement (“Post-registration Approval”). Mr. Kopfli also agreed, as of Post-registration Approval, to resign as Chief Executive Officer of Chromocell Corporation although he could continue to serve on the Channel board of directors of Chromocell Corporation, including as its Channel board of